Join Growin Stock Community!
Beta
Back to RXRX.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
cash-and-debt-chart

RXRX Cash & Debt

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

As of Q1'26, RXRX's cash and short-term investments stood at $654M USD, reflecting a moderate increase from $743M in Q4'25 but remaining below the recent peak. Total debt was reported at $72M USD, continuing a downward trajectory from $78M in the prior quarter, resulting in a strong net cash position of approximately $582M. Over the period from Q2'23 to Q1'26, cash levels exhibited volatility with an overall upward trend, starting at $406M and climbing to a high of $743M in Q4'25 before a slight pullback, driven by notable surges in Q2'24 ($474M) and Q3'25 ($660M). Debt, meanwhile, rose sharply from $53M in Q2'23 to $108M in Q4'24 amid expansion phases, but has since declined steadily to $72M, enhancing liquidity and reducing leverage risks for the biotech firm. This pattern underscores improving financial stability despite operational fluctuations.